Finally, we tested the effect of DAC combination in targeting immunophenotypically defined LSCs (live CD33 + CD38- CD34 + cells) from human primary AML samples (Supplementary Figure 12; Supplementary table 1). Here, CD38 is linked to acute myeloid leukemia.